EpiBiologics
EpiBiologics Raises $107M Series B | Protein Degradation Platform
EpiBiologics Closes $107M Series B
EpiBiologics, developing tissue-selective extracellular protein degradation therapeutics, has raised $107 million in Series B funding.
Key Highlights
- Novel protein degradation approach
- Tissue-selective targeting
- Strong biotech investor support
Company Overview
EpiBiologics is developing a new class of therapeutics that selectively degrade disease-causing proteins outside of cells, opening new therapeutic possibilities for previously undruggable targets.
Company Info
Investors (2)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started